Dr John Goodlad

 

john.goodlad@nhs.net

 

Consultant Haematopathologist

Department of Pathology

Level 3

Laboratory Medicine Building

Queen Elizabeth University Hospital

1345 Govan Rd

Glasgow

G51 4TF

Biography

John Goodlad is a Consultant Haematopathologist with NHS Greater Glasgow and Clyde and is Lead for the Integrated Haematological Malignancy Diagnostic Service.  He graduated MBChB from University of Aberdeen in 1986 and undertook post-graduate training and a higher degree at St Thomas’ Hospital, London.  He was awarded his MD from the University of Aberdeen in 1994.  Prior to relocating to Glasgow Dr Goodlad worked as a consultant in Inverness, Edinburgh and at HMDS in Leeds.   His clinical expertise is in the diagnosis of lymphomas and bone marrow disorders with a particular interest in cutaneous lymphoma.   Research interests include the translation of scientific advances into the diagnosis of Haematological malignancy and the oncogenic properties of apoptotic tumour cells.  He is author of >80 peer reviewed publications and book chapters.  Dr Goodlad is strongly committed to education in haematopathology and has lectured on the diagnosis of lymphomas at numerous courses and international pathology meetings in North America, Europe, and Asia.  He runs the annual Edinburgh Haematopathology Tutorial and is currently an executive member of the European Association for Haematopathology (Meetings Secretary Elect).  This year, he is the local organiser for the 2018 biennial meeting of the European Association for Haematopathology to be held in Edinburgh and was a member of the expert panel for the Society of Haematopathology Workshop on lymphoproliferative disorders in immune deficiency and dysregulation held in Long Beach in 2015.

Web links

Full publication list

Edinburgh Haematopathology Tutorial

Selected publications

Moody S, Escudero-Ibarz L, Wang M, Clipson A, Ochoa Ruiz E, Dunn-Walters D, Xue X, Zeng N, Robson A, Chuang SS, Cogliatti S, Liu H, Goodlad J, Ashton-Key M, Raderer M, Bi Y, Du MQ. Significant association between TNFAIP3 inactivation and biased IGHV4-34 usage in MALT lymphoma. J Pathol. 2017 Jul 6. doi: 10.1002/path.4933. [Epub ahead of print] PubMed: 28682481. 


Goodlad JR. Epstein-Barr Virus-associated Lymphoproliferative Disorders in the Skin. Surg Pathol Clin. 2017 Jun;10(2):429-453. doi: 10.1016/j.path.2017.01.001. Epub 2017 Mar 18. Review. PubMed: 28477890. 


Natkunam Y, Goodlad JR, Chadburn A, de Jong D, Gratzinger D, Chan JK, Said J, Jaffe ES. EBV-Positive B-Cell Proliferations of Varied Malignant Potential: 2015 SH/EAHP Workshop Report-Part 1. Am J Clin Pathol. 2017 Feb 1;147(2):129-152. doi:10.1093/ajcp/aqw214. PubMed: 28395107.

Chadburn A, Said J, Gratzinger D, Chan JK, de Jong D, Jaffe ES, Natkunam Y, Goodlad JR. HHV8/KSHV-Positive Lymphoproliferative Disorders and the Spectrum of Plasmablastic and Plasma Cell Neoplasms: 2015 SH/EAHP Workshop Report- Part 3. Am J Clin Pathol. 2017 Feb 1;147(2):171-187. doi: 10.1093/ajcp/aqw218. PubMed: 28395104.

Ford CA, Petrova S, Pound JD, Voss JJ, Melville L, Paterson M, Farnworth SL, Gallimore AM, Cuff S, Wheadon H, Dobbin E, Ogden CA, Dumitriu IE, Dunbar DR, Murray PG, Ruckerl D, Allen JE, Hume DA, van Rooijen N, Goodlad JR, Freeman TC, Gregory CD. Oncogenic properties of apoptotic tumor cells in aggressive B cell lymphoma. Curr Biol. 2015 Mar 2;25(5):577-88. doi: 10.1016/j.cub.2014.12.059. Epub 2015 Feb 19. PubMed: 25702581; PubMed Central PMCID: PMC4353688.